Navigation Links
Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Date:6/1/2009

e chemotherapy treatment.

"We are pleased that the PIX 301 EXTEND trial of pixantrone demonstrated a long-lasting clinical benefit in this heavily pretreated relapsed/refractory group of patients with aggressive NHL and look forward to completing the New Drug Application submission later this month," said James A. Bianco, M.D., Chief Executive Officer of CTI. "Given the lack of approved therapies for this resistant group of patients with aggressive NHL, we believe pixantrone offers a valuable therapy for this unmet medical need."

The most common grade 3, 4 adverse event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3, 4 febrile neutropenia was only 7.4% versus 3.0% in the comparator arm. Grade 3, 4 infections had a similar incidence in both study arms (18% vs. 13%). Although the grade 3, 4 cardiac disorder was similar among the two treatment groups (1.5% vs. 1.5%), there was a slightly higher incidence of serious cardiac disorders in patients treated with pixantrone than among patients who received comparator agents (8.8% vs. 4.5%). Events considered cardiac disorders included cardiac arrest, congestive heart failure, myocardial infarction, cyanosis, pericardial effusion, and tachycardia.

The ASCO poster is available at http://www.celltherapeutics.com/investor_updates.

In April 2009, CTI began a rolling submission of a New Drug Application ("NDA") with the U.S. Food and Drug Administration (the "FDA") for pixantrone to treat relapsed or refractory aggressive NHL. CTI expects to complete the submission this month and will request priority review which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009.

'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
2. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
3. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
4. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
5. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
6. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
7. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
8. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
9. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
10. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
11. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) ... the three months ended March 31, 2015 and provided ... in Canadian dollars. Effective July 17, ... May 31 to December 31. As a result of ... for the three months ended March 31, 2015, while ...
(Date:5/5/2015)... 05, 2015 VetStem Biopharma, proudly ... Health, Jeffrey Schaffer, DVM, as Director of Veterinary ... years of experience in the veterinary regenerative medicine ... to our veterinarian lead organization”. Dr. Alexis ... Schaffer will be responsible for all technical activities ...
(Date:5/5/2015)... MILFORD, Mass. , May 5, 2015 ... a strategic alliance which offers a first-of-its-kind platform that ... patient access to lab results, transforms the way patients ... Luminate Health provides a HIPAA-compliant ... patients to access, manage, and understand their lab results, ...
(Date:5/5/2015)... May 5, 2015  Renova™ Therapeutics, a biopharmaceutical ... failure and other chronic diseases, has engaged RAND ... designed to reflect the healthcare patterns of multiple ... will be used to characterize the impact the ... on those groups of patients and the overall ...
Breaking Biology Technology:Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3
... First Develop Powerful Tools for Detecting Ovarian Cancer Earlier ... BD (Becton, Dickinson and Company) (NYSE: BDX ... of a worldwide development and supply agreement for oncology ... will develop diagnostic products that incorporate Fujirebio Diagnostics, cancer ...
... Corporation,s (NYSE AMEX LLC: ETC) ("ETC" or the ... of Mr. Ray Wyngarden as Western Regional Sales ... expanding market awareness of the BARA-MED(R) XD Monoplace ... the western portion of the United States.Mr. Wyngarden,s ...
... has announced that it has produced a synthetic H1N1 swine flu ... has developed the vaccine based on the same Replikins peptide technology ... current H1N1 outbreak/pandemic was on its way. , ... ...
Cached Biology Technology:BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 2BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 3BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 4Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff 2Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff 3H1N1 Influenza "Swine Flu" Peptide Vaccine Now Available For Testing Worldwide 2
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... the "Global Gesture Recognition Market in Automotive Sector ... analysts forecast the Global Gesture Recognition market in Automotive ... the period 2013-2018. Gesture recognition is the ... different gestures of an individual. Gesture recognition technology can ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition ... Report" report to their offering. This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... Horizon oil spill, nearly 800,000 gallons of chemical dispersant were ... of the wellhead nearly one mile deep in the Gulf ... well the strategy worked at breaking up oil droplets, Woods ... colleagues report that a major component of the dispersant itself ...
... in Kosterhavet National Park in 2007 has now been ... , a form of nemertean or ribbon worm, has ... of Gothenburg, Sweden, using DNA technology. "We,ve shown ... highly labour-intensive way of describing a new species. Developments ...
... have invented a technique that uses inexpensive paper to ... analysis. The innovation represents a way to enhance ... those that test for diabetes and pregnancy. "With ... measure things like pH or blood sugar, but you ...
Cached Biology News:First study of dispersants in Gulf spill suggests a prolonged deepwater fate 2First study of dispersants in Gulf spill suggests a prolonged deepwater fate 3First study of dispersants in Gulf spill suggests a prolonged deepwater fate 4Researchers register new species using DNA-based description 2New lab-on-chip advance uses low-cost, disposable paper strips 2New lab-on-chip advance uses low-cost, disposable paper strips 3
... Helios gene gun optimization kit provides a ... parameters affecting particle delivery with the Helios ... each of 0.6 micrometer, 1.0 micrometer, and ... a cartridge kit, that provides 0.5 g ...
... be used to test the crossreactivity of ... that are commonly used as blocking reagents ... for 21 different protein preparations on a ... and species specificity, QC of purified antibodies, ...
High-throughput DNA preparation and end sequencing of BAC libraries. 3730xl DNA sequencers. LIMS tracking utilizing Geospiza's Finch system. Full-length BAC sequencing also available. Our expertise h...
... a full length insert sequencing service for ... and fosmids. Agencourt utilizes unique library ... There are several features that allow ... with rapid turnaround including our patented magnetic ...
Biology Products: